Mazziotti, Gherardo
Pedersini, Rebecca
Vena, Walter
Cosentini, Deborah
Carrone, Flaminia
Pigni, Stella
Simoncini, Edda L.
Torrisi, Rosalba
Zambelli, Alberto
Farina, Davide
Balzarini, Luca
Lania, Andrea G. http://orcid.org/0000-0002-5380-2141
Berruti, Alfredo
Article History
Received: 21 April 2022
Accepted: 9 July 2022
First Online: 28 July 2022
Declarations
:
: The Authors declare no competing non-financial interests but the following competing financial interests: Dr. Mazziotti received consultancy fees from Novartis, Ipsen, Eli Lilly and lecture fees from Amgen and Abiogen, outside the submitted work; Dr. Vena received grants from IBSA Pharmaceutical outside the submitted work; Dr. Torrisi received research grants from Pfizer, consultancy fees from MSD and lecture fees from Pfizer, Eli Lilly, EISAI and Genomic Health outside the submitted work; Dr. Zambelli received consultancy fees from Roche, Novartis, Pfizer, Eli Lilly & Co., AstraZeneca, Genomic Health; Dr. Lania received grants from Pfizer and consultancy fees from Ipsen, outside the submitted work; Dr. Berruti reports receiving grants and personal fees from Janssen Cilag, grants and personal fees from Astellas, and personal fees from Bayer outside the submitted work.
: All the procedures performed in the study were in accordance with the ethical standards of the Ethics Committees of IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy, Spedali Civili Hspital of Brescia, Italy and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All the enrolled subjects gave their informed consent to use the clinical and biochemical data for research purposes.